HLA-B Antigens

• 

  Subject Areas on Research

  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. 
  • A whole-genome association study of major determinants for host control of HIV-1. 
  • Allele assignment for HLA-A, -B, and -C genes to the Tenth International Histocompatibility Workshop cell lines. 
  • Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. 
  • Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. 
  • Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Branhamella catarrhalis activates human B lymphocytes following interactions with surface IgD and class I major histocompatibility complex antigens. 
  • CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. 
  • Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 
  • Cellular immune response to cryptic epitopes during therapeutic gene transfer. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. 
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. 
  • Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. 
  • Cysteines in the transmembrane region of major histocompatibility complex antigens are fatty acylated via thioester bonds. 
  • DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. 
  • Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. 
  • Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. 
  • Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. 
  • Evidence for linkage of HLA loci in juvenile idiopathic oligoarthritis: independent effects of HLA-A and HLA-DRB1. 
  • Expression of class I histocompatibility antigens on human T-B lymphoblast hybrids. 
  • Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. 
  • Genetic predisposition of life-threatening antiepileptic-induced skin reactions. 
  • Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 
  • Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. 
  • Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. 
  • Genomics and biology come together to fight HIV. 
  • HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. 
  • HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. 
  • HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. 
  • HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. 
  • HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 
  • HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. 
  • High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. 
  • Host determinants of HIV-1 control in African Americans. 
  • Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. 
  • Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. 
  • Human leukocyte antigens and drug hypersensitivity. 
  • Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. 
  • Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians. 
  • Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. 
  • Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. 
  • Medical genetics: a marker for Stevens-Johnson syndrome. 
  • Molecular analysis of HLA-B35 alleles and their relationship to HLA-B15 alleles. 
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. 
  • Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. 
  • Pharmacogenetics of toxic epidermal necrolysis. 
  • Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. 
  • Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. 
  • Predicting HLA genotypes using unphased and flanking single-nucleotide polymorphisms in Han Chinese population. 
  • Proper multivariate conditional autoregressive models for spatial data analysis. 
  • Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. 
  • T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction. 
  • The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. 
  • The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. 
  • The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. 
  • The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia. 
  • Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. 
  • Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. 
  • Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. 
  • Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology. 
• 

  Keywords of People

  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology